The Yorkshire Cancer Research 2026 Special COVID-19 Vaccination Funding Round supports clinical trials investigating whether COVID-19 mRNA vaccination can improve outcomes in patients receiving cancer immunotherapy.
The call follows emerging clinical evidence suggesting commercially available COVID-19 mRNA vaccines may enhance responses to immune checkpoint inhibitors. Projects may investigate feasibility and safety or evaluate the impact of vaccination on patient outcomes.
Eligibility Criteria
- Proposals must involve clinical research or clinical trials.
- Research must investigate COVID-19 mRNA vaccination in patients receiving immunotherapy.
- Vaccination should be investigated prior to the initiation of immunotherapy and/or chemoimmunotherapy.
- Projects may investigate the effect of vaccination on patient outcomes.
- Applications must comply with Yorkshire Cancer Research’s full applicant and institutional requirements.
- Applicants should review the official Information for Applicants before submission.
Funding Details
- Funding amount: Not specified by Yorkshire Cancer Research
- The scheme supports clinical research investigating COVID-19 mRNA vaccination and cancer immunotherapy.
Deadline
- Call opened: September 15, 2026
- Application deadline: October 15, 2026, 12:00 PM
- Research Advisory Panel meeting: December 3, 2026
- Funding decision: December 2026
Further Information
- Applications are submitted through the Flexigrant portal.
- New Yorkshire Cancer Research applicants must first register for a Flexigrant account.
- Applicants should consult the full 2026 Special COVID-19 Vaccination Funding Round guidance.
- Official Yorkshire Cancer Research Funding Round